It is important to devote quality time to challenge yourself and your teams on whether there is a need to strategize and rethink the way you are conducting teleconferences for your clinical trials.
Have you seen many paradigm shifts lately?
Survey uncovers key findings amid today’s explosion of data volume and sources-and the added complexity in managing clinical data.
First column in this series looks at the effectiveness of digital marketing as an outreach tool.
In the following Q&A, Guillaume Marquis-Gravel, MD, and Kevin Monroe discuss the advancements and related challenges of incorporating new technological tools in drug development, including eClinical approaches currently undertaken in the foundation’s own studies.
In the following Q&A, Guillaume Marquis-Gravel, MD, and Kevin Monroe discuss the advancements and related challenges of incorporating new technological tools in drug development, including eClinical approaches currently undertaken in the foundation’s own studies.
Remote trials have the potential to increase recruitment, reduce attrition, and make patients feel more engaged with the research.
The “citizen data scientist” is the person with no official data scientist training who uses the latest tools and technologies to handle data wrangling duties, analyze data, and create reports and models.
An increase in use of EHR systems at clinical investigative sites adds more expectations for clinical trial sponsors to comply by regulatory requirements.
An increase in use of EHR systems at clinical investigative sites adds more expectations for clinical trial sponsors to comply by regulatory requirements.
An increase in use of EHR systems at clinical investigative sites adds more expectations for clinical trial sponsors to comply by regulatory requirements.
An increase in use of EHR systems at clinical investigative sites adds more expectations for clinical trial sponsors to comply by regulatory requirements.
An increase in use of EHR systems at clinical investigative sites adds more expectations for clinical trial sponsors to comply by regulatory requirements.
This article will focus on specific requirements to ensure the Protection of Human Research Subjects (Title 45 CFR 46).
This article will focus on specific requirements to ensure the Protection of Human Research Subjects (Title 45 CFR 46).
This article will focus on specific requirements to ensure the Protection of Human Research Subjects (Title 45 CFR 46).
This article will focus on specific requirements to ensure the Protection of Human Research Subjects (Title 45 CFR 46).
This article will focus on specific requirements to ensure the Protection of Human Research Subjects (Title 45 CFR 46).
This article will focus on specific requirements to ensure the Protection of Human Research Subjects (Title 45 CFR 46).
This article will focus on specific requirements to ensure the Protection of Human Research Subjects (Title 45 CFR 46).
With outcomes from “real life” a critical compliment to clinical trial data, the importance of involving an epidemiologist at study inception is explored.
Case study demonstrates how one global mid-sized sponsor is testing the RBM waters.
Using data analytics to introduce parallel processes to optimize and accelerate clinical trials.
Right now, we only seek “perfect patients” for our trials, rendering many drugs potentially less safe or effective for those in demographics the study was not designed for.
Medicines development and clinical research are among the most heavily regulated activities on a global basis.
Randomized controlled trials establish strict inclusion and exclusion criteria in an effort to optimize the cohort of trial participants.
Utilizing a broad network of provider sites is key in overcoming failure and enabling access to high quality data.